EGFR and lung adenocarcinoma: In this report, a 63-year-old woman with lung adenocarcinoma (LADC), harboring <i>EGFR</i> exon 18 G719D and exon 21 L861Q mutations, received first-generation, <i>EGFR</i>-tyrosine kinase inhibitor (TKI) icotinib therapy.